IMCIVREE (setmelanotide acetate)
DIET AIDS · OBESITY DUE TO PROOPIOMELANOCORTIN (POMC) DEFICIENCY ·+4
RHYTHM PHARMACE
Drug class
Anti-Obesity - Melanocortin 4 (MC4) Receptor Agonist
Anti-obesity melanocortin 4 (MC4) receptor agonists are a targeted pharmacologic class designed to treat rare, severe forms of obesity caused by impaired signaling in the central leptin-melanocortin pathway. Read more about Anti-Obesity - Melanocortin 4 (MC4) Receptor Agonist
1 drugs in this class 1 manufacturers
Drugs in Anti-Obesity - Melanocortin 4 (MC4) Receptor Agonist
Filter & compare in the drug finder →
Opens the drug finder with Anti-Obesity - Melanocortin 4 (MC4) Receptor Agonist preselected. Add indication or manufacturer filters there.
Anti-obesity melanocortin 4 (MC4) receptor agonists are a targeted pharmacologic class designed to treat rare, severe forms of obesity caused by impaired signaling in the central leptin-melanocortin pathway.
Agents in this class, such as setmelanotide, selectively bind and activate MC4 receptors in the paraventricular nucleus of the hypothalamus, re-establishing downstream signaling to suppress hunger, reduce excessive caloric intake, and enhance resting energy expenditure.
Clinically, these agents are primarily indicated for chronic weight management in patients with monogenic or syndromic obesity, specifically those resulting from pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiencies, as well as Bardet-Biedl syndrome.
-
fda.gov
Anti-obesity melanocortin 4 (MC4) receptor agonists are a targeted pharmacologic class designed to treat rare, severe forms of obesity caused by impaired signaling in the central leptin-melanocortin pathway Clinically, these agents are primarily indicated for chronic weight management in patients with monogenic or syndromic obesity, specifically those resulting from pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiencies, as well...
-
nih.gov
Anti-obesity melanocortin 4 (MC4) receptor agonists are a targeted pharmacologic class designed to treat rare, severe forms of obesity caused by impaired signaling in the central leptin-melanocortin pathway
-
fda.gov
Agents in this class, such as setmelanotide, selectively bind and activate MC4 receptors in the paraventricular nucleus of the hypothalamus, re-establishing downstream signaling to suppress hunger, reduce excessive caloric intake, and enhance resting energy expenditure Clinically, these agents are primarily indicated for chronic weight management in patients with monogenic or syndromic obesity, specifically those resulting from pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin ...
-
fda.gov
Agents in this class, such as setmelanotide, selectively bind and activate MC4 receptors in the paraventricular nucleus of the hypothalamus, re-establishing downstream signaling to suppress hunger, reduce excessive caloric intake, and enhance resting energy expenditure
-
nih.gov
Agents in this class, such as setmelanotide, selectively bind and activate MC4 receptors in the paraventricular nucleus of the hypothalamus, re-establishing downstream signaling to suppress hunger, reduce excessive caloric intake, and enhance resting energy expenditure
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.